Kevan Hartshorn
Overview
Explore the profile of Kevan Hartshorn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
875
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singh S, Zhao Q, Sachs T, Hartshorn K
Case Rep Oncol Med
. 2023 May;
2023:1768926.
PMID: 37153719
We present a distinctive case of solid pseudopapillary neoplasm as seen in a 44-year-old woman who presented with an abdominal mass but unremarkable labs with no elevation in any of...
2.
Boehmer U, Potter J, Clark M, Winter M, Berklein F, Ceballos R, et al.
J Cancer Surviv
. 2021 Apr;
16(2):445-454.
PMID: 33851339
Purpose: The purpose of this study was to examine receipt of follow-up surveillance among sexual minority and heterosexual survivors and identify survivor-, physician-, and practice-level characteristics associated with follow-up surveillance....
3.
Boehmer U, Potter J, Clark M, Ozonoff A, Winter M, Berklein F, et al.
Support Care Cancer
. 2021 Mar;
29(10):5821-5830.
PMID: 33742243
Objective: The purpose of this study was to determine the association of physical and psychological symptoms with health care utilization in sexual minority and heterosexual colorectal cancer survivors. Methods: Four...
4.
Ando K, Ozonoff A, Lee S, Voisine M, Parker J, Nakanishi R, et al.
Clin Colorectal Cancer
. 2021 Mar;
20(2):e129-e138.
PMID: 33731288
Purpose: The camptothecin (CPT) analogs topotecan and irinotecan specifically target topoisomerase I (topoI) and are used to treat colorectal, gastric, and pancreatic cancer. Response rate for this class of drug...
5.
Hsieh I, White M, Hoeksema M, Deluna X, Hartshorn K
PLoS One
. 2021 Feb;
16(2):e0247605.
PMID: 33635872
Neutrophils participate in the early phase of the innate response to uncomplicated influenza A virus (IAV) infection but also are a major component in later stages of severe IAV or...
6.
Keating M, Giscombe L, Tannous T, Hartshorn K
Case Rep Oncol Med
. 2019 Oct;
2019:3847672.
PMID: 31565451
Pembrolizumab and other immunotherapies now play a prominent role in the treatment of metastatic colon cancer. Clinicians have achieved significant response rates even in heavily pretreated patients, particularly those with...
7.
Elias R, Hartshorn K, Rahma O, Lin N, Snyder-Cappione J
Semin Oncol
. 2018 Dec;
45(4):187-200.
PMID: 30539714
The advent of immune checkpoint inhibitors (ICIs) has changed the landscape of cancer treatment. Older adults represent the majority of cancer patients; however, direct data evaluating ICIs in this patient...
8.
Sheikh A, Yameen H, Hartshorn K
Curr Oncol Rep
. 2018 Nov;
20(12):102.
PMID: 30456634
Purpose Of Review: Rectal cancer is predominantly a disease of older adults but current guidelines do not incorporate the associated specific challenges leading to wide variation in the delivery of...
9.
Shin T, Inagaki E, Ganta T, Hartshorn K, Litle V, Suzuki K
Ann Thorac Surg
. 2018 Sep;
107(3):e199-e201.
PMID: 30218665
Tumor lysis syndrome is a life-threatening complication comprising hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia attributed to release of intracellular contents. Although traditionally associated with leukemia and lymphoma after chemotherapy, it is...
10.
Kumaradevan S, Lee S, Richards S, Lyle C, Zhao Q, Tapan U, et al.
Am J Pathol
. 2018 Jul;
188(8):1921-1933.
PMID: 30029779
The proto-oncogene β-catenin drives colorectal cancer (CRC) tumorigenesis. Casitas B-lineage lymphoma (c-Cbl) inhibits CRC tumor growth through targeting nuclear β-catenin by a poorly understood mechanism. In addition, the role of...